Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,933 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Group C Clear all
Terminated Phase 1Phase 2 Interventional Results available

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

NCT02711137
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 3 Interventional

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

NCT02032277
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Cyclophosphamide, Placebo, Doxorubicin, Paclitaxel, Carboplatin, Veliparib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
61
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 21, 2026, 11:14 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Germ Cell Tumor and Testicular Tumor DNA Registry

NCT02099734
View directory record Official record
Conditions
Germ Cell Tumor, Testicular Tumor
Interventions
Questionnaires, sample of blood or saliva
Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2028
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants

NCT07102316
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TPIP F2, TPIP F3
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 21, 2026, 11:14 PM EDT
Recruiting Not applicable Interventional

A Study of a Side Effects and Resource Navigation Program for People With Cancer

NCT07646847
View directory record Official record
Conditions
Kidney Cancer, Bladder Cancer, Breast Cancer, Lung Cancer
Interventions
Immunotherapy CARE Program
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 11:14 PM EDT
Recruiting Not applicable Interventional

Upper Extremity Functional Electrical Stimulation (FES) for Restoration of Upper Extremity Function After Spinal Cord Injury (SCI)

NCT06672458
View directory record Official record
Conditions
Spinal Cord Injuries, Peripheral Nerve Injuries
Interventions
MyndMove Short Term Therapy, Conventional Short Term Therapy, MyndMove Long Term Therapy
Device · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults

NCT02837692
View directory record Official record
Conditions
Healthy
Interventions
JNJ-42847922 10 milligram (mg), JNJ-42847922 20 mg, JNJ-42847922 40 mg, JNJ-42847922 60 or 80 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Cypress, California • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Oct 21, 2026, 11:14 PM EDT
Terminated Phase 3 Interventional Results available

A Mobile Application to Promote Self-management and Improve Outcomes in Heart Failure

NCT04755816
View directory record Official record
Conditions
Heart Failure
Interventions
Sodium intervention, Clinical worsening intervention, Educational content
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Birmingham, Alabama • Stanford, California • Altanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 21, 2026, 11:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

In-situ Evaluation of Anti-caries Technology

NCT01650493
View directory record Official record
Conditions
Caries
Interventions
Clinpro 5000, MI Paste Plus, Tom's of Maine
Device
Lead sponsor
Solventum US LLC
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 4 Interventional Results available

Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease

NCT02287909
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel, Ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration

NCT01737944
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate (MTX)
Drug
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 25, 2014 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®

NCT00269477
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
15 Years to 23 Years
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
8
States / cities
Atlanta, Georgia • Marietta, Georgia • Woburn, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 2 Interventional

High-intensity Exercise and Fall Prevention Boot Camp for Parkinson's Disease

NCT02230267
View directory record Official record
Conditions
Parkinson's Disease
Interventions
High intensity exercise and balance training, Usual care arm exercise
Other
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
45 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

NCT02839330
View directory record Official record
Conditions
Avian Influenza
Interventions
aH5N1c, Placebo
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
3,196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
26
States / cities
Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 21, 2026, 11:14 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Centering Those Engaged in Transactional Sex: A PrEP Innovation for Getting To Zero

NCT05929521
View directory record Official record
Conditions
Sex Work, Pre-Exposure Prophylaxis
Interventions
C-PrEP+
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Not applicable Interventional Results available

Acceptance-based Group Intervention for Binge Eating

NCT01757847
View directory record Official record
Conditions
Binge-Eating Disorder
Interventions
Acceptance and Commitment Therapy (ACT), Brief MOVE-II control group intervention
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Not applicable Interventional Results available

Optimizing Dementia Care

NCT02585232
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Dementia, Vascular, Caregivers, Veterans
Interventions
Counseling (C), Care Consultation (CC)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
19 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

NCT04228783
View directory record Official record
Conditions
Ebola
Interventions
Ad26.ZEBOV, MVA-BN-Filo, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
974 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
7
States / cities
Mobile, Alabama • Tempe, Arizona • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers

NCT01674218
View directory record Official record
Conditions
Tuberculosis
Interventions
Moxifloxacin, PA-824, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2014 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults

NCT03220724
View directory record Official record
Conditions
HIV Infections
Interventions
CH505TF, CH505w53, CH505w78, CH505 M5, GLA-SE adjuvant, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

NCT01728324
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
BI 207127-placebo: 8-week treatment, Ribavirin: 24-week treatment, BI 207127: 24-week treatment, Faldaprevir: 24-week treatment, Ribavirin-placebo: 8-week treatment, Faldaprevir-placebo: 8-week treatment, Faldaprevir: 16-week treatment, Ribavirin: 16-week treatment, RBV: 24-week treatment, BI 207127: 16-week treatment
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
31
States / cities
North Little Rock, Arkansas • Anaheim, California • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 21, 2026, 11:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease

NCT03136679
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
40 Years and older
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 21, 2026, 11:14 PM EDT
Completed Phase 1 Interventional

A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects

NCT01011959
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
REGN88
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
24
States / cities
Santa Maria, California • Boca Raton, Florida • Clearwater, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 21, 2026, 11:14 PM EDT
Recruiting Not applicable Interventional

Sustaining Physical Activity After Cancer Exercise Sessions

NCT06359210
View directory record Official record
Conditions
Exercise Oncology, Physical Activity Behavior, Behavior Change Interventions
Interventions
Responder Monthly Behavior Change Discussion Sessions, Incomplete Responder Monthly Behavior Change Discussion Sessions, Incomplete Responder Monthly Behavior Change Discussion Sessions + Bi-Weekly Exercise Sessions
Behavioral
Lead sponsor
Colorado State University
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Aurora, Colorado • Fort Collins, Colorado • Laramie, Wyoming
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 21, 2026, 11:14 PM EDT